| [1] Parkin DM, Pisani P, Ferlay J, et al. Global cancer statistics[J]. CA Cancer J Clin, 1999, 49(1): 33-64.[2] Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine[J]. Pharmgenomics Pers Med, 2014, 7: 329-338.[3] Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2002, 20(3): 719-726.[4] Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk[J]. Nat Rev Mol Cell Biol, 2014, 15(3): 155-162.[5] Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer[J]. Curr Opin Urol, 2013, 23(5): 472-478.[6] Ng VC, Johnson JJ, Cuellar S. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer[J]. J Oncol Pharm Pract, 2015, 21(6): 433-442.[7] Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma[J]. Onco Targets Ther, 2014, 7: 575-585.[8] Rolfo C, Giovannetti E, Hong DS, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors[J]. Cancer Treat Rev, 2014, 40(8): 990-1004.[9] Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer[J]. J Natl Compr Canc Netw, 2013, 11(6): 670-678.[10] Bakarakos P, Theohari I, Nomikos A, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas[J]. Histopathology, 2010, 56(7): 876-882.[11] Ueng SH, Chen SC, Chang YS, et al. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas[J]. Int J Clin Exp Pathol, 2012, 5(8): 806-813.[12] Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Statist Med, 1998, 17(24): 2815-2834.[13] Mei XD, Su H, Song J, et al. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a Meta-analysis[J]. Biosci Trends, 2013, 7(1): 42-49.[14] Qiu ZX, Zhang K, Qiu XS, et al. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis[J]. PLoS One, 2013, 8(12): e81451.[15] An J, Jeong H, Lee Y, et al. Phosphorylated Akt and phosphorylated mTOR expression in breast invasive carcinomas: Analysis of 530 cases[J]. Breast Cancer, 2010, 13(4): 337.[16] Bose S, Chandran S, Mirocha JM, et al. The Akt pathway in human breast cancer: A tissue-array-based analysis[J]. Mod Pathol, 2006, 19(2): 238-245.[17] Ma BL, Shan MH, Sun G, et al. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer[J]. Mol Med Rep, 2015, 12(4): 5246-5254.[18] 刘雅昕, 李惠平, 赵红梅, 等. mTOR表达与雌激素受体阳性乳腺癌辅助内分泌治疗预后的关系[J]. 癌症进展, 2013,11 (3): 254-258,269.[19] 虞蕾楠, 姚广裕, 胡晓磊, 等. 雌激素受体阳性乳腺癌中mTOR蛋白的表达及与内分泌辅助治疗预后的关系[J]. 现代生物医学进展, 2015, 15(8): 1418-1420.[20] Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison[J]. PLoS Negl Trop Dis, 2013, 7(5): e2195.[21] Cai W, Shi Y, Zhao Q. Relationship between expression of mTOR and prognosis of early stage non-small cell lung cancer[J]. Zhonghua Zhong Liu Za Zhi, 2014, 36(2): 120-122.[22] Leal P, Garcia P, Sandoval A, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma[J]. Arch Pathol Lab Med, 2013, 137(4): 552-557.[23] Xiao L, Wang YC, Li WS, et al. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray[J]. J Exp Clin Cancer Res, 2009, 28: 152.[24] 俞 媛,陈晓蓉.PI3K/Akt/mTOR信号转导道路在肝细胞癌发生发展中的作用[J].临床肝胆病杂志,2014,30(9):954-957.[25] 叶 荆, 王 蓓, 陈建彬, 等. PI3K/Akt/mTOR通路抑制剂依维莫司治疗晚期乳腺癌的研究进展[J]. 肿瘤, 2015,35 (2): 221-224.[26] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.[27] Ito Y, Masuda N, Iwata H, et al. Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2 [J]. Gan To Kagaku Ryoho, 2015, 42(1): 67-75.[28] André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol, 2014,15(6): 580-591.[29] 张 莹,李春艳,崔泽实,等.TSG101与HIF-1α在乳腺癌组织中的表达及意义[J]. 中国实用内科杂志,2014,34(增1):96-98. |
